Journal article
Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review
Acta Pharmacologica Sinica, Vol.43, pp.2173-2190
2022
PMCID: PMC8767044
PMID: 35046517
Abstract
Colchicine is an ancient herbal drug derived from Colchicum autumnale. It was first used to treat familial Mediterranean fever and gout. Based on its unique efficacy as an anti-inflammatory agent, colchicine has been used in the therapy of cardiovascular diseases including coronary artery disease, atherosclerosis, recurrent pericarditis, vascular restenosis, heart failure, and myocardial infarction. More recently, colchicine has also shown therapeutic efficacy in alleviating cardiovascular complications of COVID-19. COLCOT and LoDoCo2 are two milestone clinical trials that confirm the curative effect of long-term administration of colchicine in reducing the incidence of cardiovascular events in patients with coronary artery disease. There is growing interest in studying the anti-inflammatory mechanisms of colchicine. The anti-inflammatory action of colchicine is mediated mainly through inhibiting the assembly of microtubules. At the cellular level, colchicine inhibits the following: (1) endothelial cell dysfunction and inflammation; (2) smooth muscle cell proliferation and migration; (3) macrophage chemotaxis, migration, and adhesion; (4) platelet activation. At the molecular level, colchicine reduces proinflammatory cytokine release and inhibits NF-κB signaling and NLRP3 inflammasome activation. In this review, we summarize the current clinical trials with proven curative effect of colchicine in treating cardiovascular diseases. We also systematically discuss the mechanisms of colchicine action in cardiovascular therapeutics. Altogether, colchicine, a bioactive constituent from an ancient medicinal herb, exerts unique anti-inflammatory effects and prominent cardiovascular actions, and will charter a new page in cardiovascular medicine.
Details
- Title
- Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review
- Authors
- Fan-Shun Zhang (Author) - University of Science and Technology of ChinaQing-Ze He (Author) - University of Science and Technology of ChinaChengxue Helena Qin (Author) - Monash UniversityPeter J Little (Author) - University of the Sunshine Coast, Queensland, School of Health and Behavioural Sciences - LegacyJian-Ping Weng (Author) - University of Science and Technology of ChinaSuo-Wen Xu (Corresponding Author) - University of Science and Technology of China
- Publication details
- Acta Pharmacologica Sinica, Vol.43, pp.2173-2190
- Publisher
- Nature Publishing Group
- DOI
- 10.1038/s41401-021-00835-w
- ISSN
- 1745-7254
- PMID
- 35046517; PMC8767044
- Grant note
- XDB38010100 / Strategic Priority Research Program of Chinese Academy of Sciences; Chinese Academy of Sciences 2017BT01S131 / Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program 202104j07020051 / Anhui Provincial Key Research and Development Program Hefei Municipal Development and Reform Commission CXGG02 / Program for Innovative Research Team of The First Affiliated Hospital of USTC BJ9100000005 / Hefei Comprehensive National Science Center 81941022; 815300254; 82070464 / National Natural Science Foundation of China; National Natural Science Foundation of China (NSFC) 2021YFC2500500 / National Key R&D Program of China
- Organisation Unit
- University of the Sunshine Coast, Queensland; School of Health and Behavioural Sciences - Legacy; School of Health
- Language
- English
- Record Identifier
- 99603408202621
- Output Type
- Journal article
Metrics
30 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
Highly Cited Paper
- Collaboration types
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Chemistry, Multidisciplinary
- Pharmacology & Pharmacy
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites